Vicor Technologies to Present PD2i Vital Sign Application and Findings at the Smart Monitoring 2008 Forum

Market Wire, August, 2008

David Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor will present its proprietary PD2i Vital Sign (PD2i VS) technology for risk stratifying trauma severity at the Smart Monitoring 2008 Forum on August 10, 2008 in St. Petersburg Beach, Florida. The Smart Monitoring Forum immediately precedes the Department of Defense's (DOD) 2008 Advanced Technological Assessment of Critical Combat Casualties (ATACCC) Conference.

Vicor Technologies is a medical diagnostics company that has developed the PD2i, a patented, proprietary algorithm that is now in trials for FDA 510(k) approval for use in risk stratifying a) the severity of injury and probability of survival of critically injured soldiers and civilians (PD2i Vital Sign) and b) patients who are at high or low risk of suffering sudden cardiac death (PD2i Cardiac Analyzer).

Vicor's presentation at Smart Monitoring 2008 will detail the application of its PD2i VS as an enhanced vital sign measurement to more accurately risk stratify trauma severity and the probability of survival in the critically injured. It will also provide a review of trial results conducted under a Collaborative Research and Development Agreement (CRADA) between Vicor and the U.S. Army Institute of Surgical Research (USAISR) begun in January 2008. To date, under the CRADA, Vicor has completed two studies (one human, one animal) and is in the process of completing two more studies. Vicor anticipates filing with the FDA a 510(k) application for the PD2i VS this year.

"We're extremely pleased and honored to be invited to present our technology, and recent positive trial results before this forum of prominent and influential military, medical, scientific, business, and industry professionals," stated Mr. Fater. "As Vicor moves steadily toward commercialization of its technology applications, our presence at prestigious events such as Smart Monitoring and ATACCC gain Vicor important visibility, and significantly increases our opportunity to explore new strategic relationships and collaborative efforts that enable us to identify new applications for the PD2i," Mr. Fater concluded.

Sponsored by the Resuscitation Research Laboratory of the University of Texas Medical Branch, the Smart Monitoring Forum is an open discussion focused on vital signs monitoring for combat physicians, medics, corpsmen, and nurses to discuss needs, and how current monitoring technologies meet/do not meet those needs. It also provides an opportunity for industry to present new and emerging monitoring technologies and share how their product(s) can contribute to the medical care of military and civilian trauma.

The ATACCC is the DOD's premier scientific meeting. ATACCC addresses critical advances in trauma medicine and the unique medical needs of the war fighter, with a focus on the growing and changing operational issues and identifies technologies available today and in the future that can be used to meet these increasingly complex goals.

Additional information about the Smart Monitoring 2008 Forum and ATACCC 2008 Conference may be found at http://www.utmb.edu/rrl/Announcement.html and https://www.usaccc.org/ATACCC/index.htm , respectively.

About Vicor Technologies, Inc.

Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on the development of innovative diagnostics and therapeutics. Both Vicor's PD2i Vital Sign (PD2i VS) and PD2i Cardiac Analyzer employ the firm's patented, proprietary PD2i algorithm, a deterministic, non-linear analytic measure that accurately evaluates electrophysiological potentials with high sensitivity and high specificity to predict future pathological events.

The PD2i VS enables risk stratification of trauma severity to identify those in need of immediate life saving intervention and improve emergency triage efforts. The PD2i VS is currently in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. Vicor anticipates filing with the FDA a 510(k) application for the PD2i VS this year.

The PD2i Cardiac Analyzer identifies patients at risk of suffering a fatal arrhythmic event or sudden cardiac death (SCD) within six months. The PD2i Cardiac Analyzer is currently involved in a multi-site, multi-year trial (the VITAL Trial) being conducted by the Harvard Clinical Research Institute. Vicor anticipates completion of the VITAL Trial one year following the enrollment of the last patient and FDA approval to commercialize use of the PD2i Cardiac Analyzer immediately thereafter.

Vicor anticipates developing additional applications using the PD2i algorithm to enable early detection of Alzheimer's Disease, and a variety of other disorders and diseases.

More information about Vicor Technologies may be found at www.vicortech.com .

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein